




SIMCERE PHARMACEUTICAL GROUP LIMITED

2022 R&D DAY

STOCK CODE: 2096.HK



tion materials have been prepared by Sincere Pharmaceutical Group Limited 先聲藥業集團有限公司 (the "Company") in accordance with the prevailing economic, legal, market and other conditions and for
it should be understood that any subsequent development could affect the information contained in these presentation materials and that the Company and its advisers and representatives shall not be obliged to make any revision, amendment or addition to such information. It is intended that this may constitute a preliminary offer and should not be taken as a recommendation
regarding the securities of the Company (the "Securities").

Information contained in these presentation materials has not been reviewed by any regulatory authorities, and has not been independently verified. The Company does not intend to provide, and you should not rely on,
these presentation materials to obtain a complete picture of the Company's financial position, performance, prospects, risks, or other matters. The Company and its advisers and representatives shall not be responsible for any loss or damage caused by reliance on the accuracy, reliability, completeness, fairness,
timeliness or otherwise of the information contained in these presentation materials. The Company and its advisers and representatives shall not be responsible for any loss or damage caused by reliance on the accuracy, reliability, completeness, fairness,
timeliness or otherwise of the information contained in these presentation materials.

These presentation materials are not intended to constitute an offer of securities or an invitation to subscribe for securities, nor are they intended to constitute an offer of securities or an invitation to subscribe for securities.
proposed prospectus or extract from a proposed version of a prospectus within the meaning of section 38B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance or an advertisement, invitation or document
advertisement or invitation within the meaning of section 40 of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) or (2) in Hong Kong to have effected an offer to the public
in accordance with the laws of Hong Kong or having applied to or received an exemption from the laws of Hong Kong and in which the Company or its advisers and representatives have not been involved.

These presentation materials are not intended to constitute an offer of securities or an invitation to subscribe for securities, nor are they intended to constitute an offer of securities or an invitation to subscribe for securities.
to risks and uncertainties, in such circumstances as to make it unlikely that the Company or its advisers and representatives will be able to provide a complete and accurate picture of the Company's financial position, performance, prospects, risks, or other matters.
information available to the public, and the Company and its advisers and representatives shall not be responsible for any loss or damage caused by reliance on the accuracy, reliability, completeness, fairness,
timeliness or otherwise of the information contained in these presentation materials. The Company and its advisers and representatives shall not be responsible for any loss or damage caused by reliance on the accuracy, reliability, completeness, fairness,
timeliness or otherwise of the information contained in these presentation materials.

These presentation materials are not intended to constitute an offer of securities or an invitation to subscribe for securities, nor are they intended to constitute an offer of securities or an invitation to subscribe for securities.
various factors, including but not limited to, changes in the economic, legal, market and other conditions, changes in the Company's financial position, performance, prospects, risks, or other matters, and changes in the
information available to the public, and the Company and its advisers and representatives shall not be responsible for any loss or damage caused by reliance on the accuracy, reliability, completeness, fairness,
timeliness or otherwise of the information contained in these presentation materials. The Company and its advisers and representatives shall not be responsible for any loss or damage caused by reliance on the accuracy, reliability, completeness, fairness,
timeliness or otherwise of the information contained in these presentation materials.

These presentation materials are not intended to constitute an offer of securities or an invitation to subscribe for securities, nor are they intended to constitute an offer of securities or an invitation to subscribe for securities.
regulatory requirements. These presentation materials shall not constitute or form part of an offer or issue of the Securities nor any solicitation, invitation or offer of purchase or subscription of the Securities. These
presentation materials are provided only for information only and shall not be relied upon and shall not be used for any purpose other than for information only. In particular, it is not
intended to constitute an offer of securities or an invitation to subscribe for securities, nor are they intended to constitute an offer of securities or an invitation to subscribe for securities.

These presentation materials are not intended to constitute an offer of securities or an invitation to subscribe for securities, nor are they intended to constitute an offer of securities or an invitation to subscribe for securities.
information available to the public, and the Company and its advisers and representatives shall not be responsible for any loss or damage caused by reliance on the accuracy, reliability, completeness, fairness,
timeliness or otherwise of the information contained in these presentation materials. The Company and its advisers and representatives shall not be responsible for any loss or damage caused by reliance on the accuracy, reliability, completeness, fairness,
timeliness or otherwise of the information contained in these presentation materials.

These presentation materials are not intended to constitute an offer of securities or an invitation to subscribe for securities, nor are they intended to constitute an offer of securities or an invitation to subscribe for securities.
subscription, or purchasing of any securities or structured products, rights, or other financial instruments, and no offer or collection has been made in respect of the purchase or subscription of
any securities.

AGENDA



01 Welcome Speech

Ren Jingsheng
Chairman of the Board & CEO

5min



02 Company Overview Strategy

Zhou Gaobo
CIO

10min



03 Pre-clinical R&D Update



04 Late-stage Oncology Pipeline

Bijoyesh Mookerjee, MD
CMO, Oncology

20min



05 Late-stage Non-oncology Pipeline

Danny Chen, PhD
SVP, neuroscience

20min



06 Strengthening BD, M&A and Investments within Global Strategy



07 Q&A - ALL

HOST : Jason Bao
Secretary of the Board



Company Overview Strategy

Zhou Gaobo
CIO

Bionpharma innovation flourishing in China while bottlenecks also emerging — industry entering innovation 2.0 era

Quality of

by domestic biotech

Biopharma innovation driven by growth patient needs,
improving healthcare reform policies and capital infusion

Intense competition and crowding limit
China's biopharma innovation

Number of IND applications in China

Clinical research programs sponsored
and pharmacos in China



Envision's journey to a Biotech pharmaceutical company



Innovative and competitively differentiated products contribute to 60%+ of Sincere's revenue

Share of innovative products in total revenue

globally since 2015
27.4%

Sanbexin®
The only newly approved stroke drug

Entered **2,400** hospitals in first year of launch
100+% growth annually, major contributor to **CNS portfolio**

ELA (Trilaciclib)
In-class comprehensive
cytotoxic-protective therapy

2021.11.29

NDA priority review
by NMPA

32.9%

45.1%

ENWEIDA (Envafolimab)
Global first subcutaneous PD-L1


2021.11.25

Approved

COS
First-in-class
myelo

2,000 patients treated

Full value chain capabilities enable Sincere's innovation aspiration



Accelerating towards innovation through in-house R&D and partner collaboration

Local innovation capabilities



Innovation Center **Boston**

- Global clinical development
- BD Development
- New opportunity with breakthrough potentials

Innovation Center **Shanghai**

Oncology & Immunology,
Pre-/clinical capability



Innovation Center **Beijing**

Neuroscience & Transl Sci
Clinical Dev, Registration, IP




Track record as partner of choice



National Key Lab **Nanjing**



Sustained R&D investment for future growth



Seasoned team with global vision



Sustained high quality growth driven by key innovative products

Projected share of innovative products in total revenue

Peak sales (USD)



Key developments expected in 2022

Joining the fight
against COVID-19

2022

Sanbexin®, **ENWEIDA®**

Innovative drugs sales

China phase III clinical trial to
be completed in H1 2022

to be launched in China in 2022

2022

Highlights

Terapeutic form. Chinese patient population receiving chemotherapy, the product has the potential of gaining huge market share and attention. is expected to be launched in China in 2022.



achieved annual sales of RMB 1.5 billion in its first year. The rapid clinical development of Sanbaxin a multi-mechanism full-course therapeutic approach.



in early April.

Innovation

Simcere has formed a new drug R&D pipeline involving 17 potential innovative drugs.

Globalization

internationalized organization and




Preclinical Drug R&D

Tang Renhong, PhD
EVP

The background of the slide features a stylized, abstract representation of a DNA double helix. The helix is composed of numerous thin, parallel lines in shades of blue, pink, and yellow, creating a sense of depth and movement. The lines are arranged in a way that suggests the three-dimensional structure of the DNA molecule. The overall color palette is soft and pastel, with a light blue and white background. The text is centered and stands out clearly against the abstract design.

Preclinical R&D Strategy and Drug Discovery Engines

Patient-Centric Drug Discovery Strategy




- **Building trust in communities where technology acceptance and execution for high-value products**



- **Building trust in communities where technology acceptance and execution for high-value products**


Proprietary platforms support diversified drug modalities




Simcere Creative platform of Protein Engineering



Function validation



SCoPE



Adapting a Drug Discovery

an end-to-end drug discovery process

Infrastructure and capability internally

Partner for agile development




Focus on the application on early stage drug discovery, such as hit generation

optimization

• Establishing data science infrastructure

• Collaborating with external partners



Project V Our Path to the Future

...focusing on exploring and creating



...to attract and unite a group of young talents in life science and for

...s with either high treatment needs or



10 directions/technologies
breakthrough potential



drug discovery



fill the gap during the transformation of research hypothesis to



therapeutics development



Building the true innovative research engine



Diseases Specific Strategies and Key Assets

Genetics, Autoimmunity, Neuroscience



Activation of Innate Immune response

- Cell surface checkpoint modulation on cytotoxic immune cells

Immune Cells Function

Tumor Cells

Cell Cycle Modulation to address treatment resistance

- Synthetic lethal at varies levels, DNA repairing, metabolism, transcription
- Critical Signal protein modulation and degradation

Cytokine and fusion protein to enhance the effect of current checkpoint modulators

- TAA and neoantigens for Immune cell engagers and ADC
- Promoting antigen presenting, Immune cell infiltration

USP1, CBL-b

Involved MoAs: TIGIT/PVRIG, PD-L1-IL15v, Pn(m)5α, MSLN-CD3, B25/Her2-ADC

• Involvement in SIRC




- **Simultaneously targeting two checkpoints for improved immune activation**

Significant Synergy Effect With T




SIM0237: PD-L1/IL15v Bifunctional Fusion Protein

Best-in-Class potential with Improved tumor control and low safety risk



Significant Tumor Growth Inhibition




NCI-H292-hPBMC xenograft model

Rationale:

- Blocking PD-1/PD-L1 signaling and deliver IL-15 directly to TME for fully activation of CD8 T cells
- Fine tune IL-15 pharmacological profile through protein engineering

Superior In Vitro Activity And I

- RAD51 plays a central role in the homologous recombination pathway





broad combination opportunities for multiple tumor types

tumors

- **Multiple combination potential with chemotherapy and other DDR pathway**

targeting therapeutics




Key role in mismatch repair (MMR) with synthetic lethal potential to microsatellite instability (MSI)

Previously disclosed inhibitor yet

Identification of Hit compound through virtual lib screening supported by machine learning algorithm

- Target plays a pivotal role in
- Current no public
- Successful identification

Computer-aided virtual screening of DNA damage-inducing agents for the identification of MMR inhibitors



Autoimmunity

Targeted Delivery of

Immunosuppressive
agents

02

Profound immuno-
suppression in disease

- Re-establish Treg/Teffs balance

Treg Biology


01

- Selectively stimulate Treg cell proliferation or its

- Minimizing the systemic side-effects


SIM0278: IL-2 mutein specifically Promote Treg Function

Differentiation through protein engineering



Ab-Steroid conjugate for Th2 suppression

Significant decrease of IgE production and inflammatory cell infiltration bring great histological improvement



200μm


Neuroscience

Strengthening our core competence in stroke neurodegenerative




Expand Sanbexin[®] to Hemorrhagic Stroke

Collagenase-induced intracerebral hemorrhage Model




Subarachnoid Hemorrhage Model


Protect Blood-Brain Barrier Integrity



Improve Dyskinesia




Improve Neuron Function



Ameliorate

SIM0417: A Novel Oral 3CL Protease Inhibitor for COVID-19

Oral 3CL protease inhibitor jointly developed with Shanghai Institute of Materia Medica



antiviral activity against wild-type strain, inhibit viral replication in lung, significantly improve lung damage caused by COVID-19.

Pharmacokinetic Properties SIM0417 has good pharmacokinetic properties *in vivo*, its lung tissue concentration is high.

No genotoxicity.

- **Good Antiviral Activity** great antiviral activity against wild-type, delta and Omicron variants, and brain tissue, significantly reduced viral load by the virus.
- **Excellent *in vivo* Pharmacokinetic Properties** SIM0417 has good pharmacokinetic properties, its lung tissue concentration is high, and it has a lower human plasma clearance.

Expected submissions in 2022

Q1

Q2

Q3

Q4

SIM0272

PRMT5
China

IND

SIM0323

CD80/IL2v
China

IND

SIM0237

PD-L1/IL15v
US

IND

SIM0237

PD-L1/IL15v
China

IND

SIM0417

3CI (COVID19)
China

IND

SIM0348

TIGIT/PVRIG
US

IND

SIM0450

PSD-95
China

IND

SIM0271

MAT2A
China

IND

SIM0348

TIGIT/PVRIG
China

IND

SIM0278

IL-2mu-Fc
US

IND

Oncology

Autoimmunity

Neuroscience

Key Takeaways for Today

1

Patient-centered principle is core of our drug R&D efforts

2

Build competence in platform

3

Improve TA-focused strategy through deeper understanding of disease biology

4

Quick and agile execution of high potential assets for clinical validation

5

Establish solid foundation of early stage innovation through Drug X for long-term growth



Late-stage Oncology Pipeline



2024




Therapeutic Area Layout

Products in China

Clinical value-oriented medicines to provide greater efficacy for cancer patients


Sincere anti-tumor products approved for

Estimated incident rates of new cancers (China)




Oncology Pipeline Layout

Maximize existing, and accelerate new medicines and combinations



Differentiated Targets and Indications

Providing novel medicines for patients with rare diseases



Key Project Introduction..

Progress in Clinical Trials

Trilaciclib: a CDK4/6 inhibitor that provides prophylactic bone marrow protection

Protects **hematopoietic stem/progenitor cells (HSPCs)** from chemotherapy and enhance the immune system through

Prevent multiple adverse events of myelosuppression through **multilineage bone marrow protection**¹⁻³


Mitigate neutropenia

avoid administration delay and



composition of T
number and

**Enhance immune response and
protect immune function**



- Change the proliferation kinetics and cell subsets in tumors to enhance the immune response



1L CRC data readout
1L TNBC data readout

Trilaciclib: accelerating the indication process in China

Stage SCLC

Only FDA-approved therapy that proactively delivers multilineage myeloprotection to extensive stage patients being treated with chemotherapy

1-3L chemotherapy (N=92)

multicenter

Design, primary analysis completed, PK and

overseas countries

primary endpoint (DSN in first cycle).

ing application submitted to China NMPA in November

* 2021: Priority review decision granted, expected to be approved in 2022

* DSN: duration of severe neutropenia

2021/2/12

On 12 February 2021, FDA fully approved

COSELA™ (Trilaciclib) for bone marrow

protection in ES-SCLC patients, which is **the**

world's first and only bone marrow

protection therapy that can reduce the

incidence of chemotherapy-induced

myelosuppression

TRACES study in China:

Phase III trial for ES-SCLC treated with

• The 1st part: safety lead-in and PK bridging

• The 2nd part: phase III trial

• The 3rd part: phase III trial


• Conditional marketing

2021/11/29

Submission of Conditional Marketing

Trilaciclib: PRESERVE trials

Enhance management of severe neutropenia in colorectal cancer patients receiving FOLFOXIRI and bevacizumab



Phase III global clinical trial for bone marrow protection in CRC patients treated with FOLFOXIRI & Bevacizumab (N=296)

- Primary Endpoint: Duration of severe neutropenia in cycle 1 and occurrence of severe neutropenia during Induction
- FPI worldwide: 16 October 2020
- FPI in China: 24 September 2021

Final results to be published in March 2022

PRESERVE 2 : TNBC (N=170)

Phase III global clinical trial of survival improvement in TNBC

0.028 0.0023 0.0016

Trilaciclib showed strong OS improvement in the TNBC randomized controlled phase II trial.

In July 2021, TNBC indication was granted Fast Track designation by the FDA.

- Primary endpoint: Overall Survival
- FPI worldwide: 15 April 2021
- FPI in China: 7 January 2022
- FPI in USA: 7 January 2022

Enrollment ongoing

Patients randomized to receive chemotherapy only (Group 1) or gem/carbo plus one of two

Copyright © 2022 Simcere. All rights reserved.

Patients randomized to receive gem/carbo

先声药业

simcere

Endostar® New Indication: malignant

thoracoabdominal effusions


Early studies have shown that Endostar® also has a positive therapeutic effect on malignant thoracoabdominal

effusions¹

comparison in 3 groups (number of cases, %)

compared with cisplatin, $P=0.05$

Endostar injection
in NSCLC in China



Endostar® is a recombinant human endo
approved for first-line treatment of advanced

Endostar® New Indication: COREMAP study

To address the urgent need of patients with malignant thoracoabdominal effusions

Patients whose expected survival is less than two weeks, the proportion of abdominal distension caused by ascites is as high as 29% (meta analysis). The incidence of intracavitary bleeding is 1.19% and is estimated to increase to 1.91% by 2030.

COREMAP : Endostar® for treatment of malignant thoracoabdominal effusions, phase III

Intra-pleural injection of recombinant human endostatin/placebo with cisplatin in treatment of malignant thoracoabdominal effusions: a multicenter, randomized, controlled trial




- Among patients with incurable tumors, the proportion of abdominal distension caused by ascites and other reasons is as high as 29%.
- According to Frost & Sullivan data, the number of malignant tumors reached 707,900 in 2019 and is estimated to increase to 756,900 by 2030.

Tumors causing malignant thoracoabdominal effusions

Tumors causing malignant thoracoabdominal effusions

- Recruitment: 105 subjects enrolled as of March 30, 2022
- Interim results analysis expected in H2 2022





Glioblastoma (GBM)

~100 cases
per annum worldwide

- The main treatment drug is **Temozolomide**
- China's annual market size for GBM is about **2B yuan**
- Temozolomide **almost ineffective** for **65%** of the patients (those with unmethylated MGMT status)

Glioblastoma (GBM)

133,000 cases
per annum worldwide

BM indication, Orphan Drug designation was granted

GBM AGILE: A trial of Pexelich in GBM

- For the GBM

First PD-L1 Antibody Approved For Subcutaneous Injection

Envafolelimab has a good safety profile as a single agent

- Envafolelimab phase II trial for advanced MSI-H/dMMR solid tumor showed it

Immunize camel
with PDL1



dAb blocking
PDL1-P
interact

2020 and approved in November 2021

2020 CSCO

N

ORR

DCR

12moPFS

12mo OS

Total

65

43.1%

61.5%

43.7%

72.9%

Treatment

Advanced

3-drugs

Treatment

failure after

34

62.5%

66.7%

62.5%

2 drugs

~80kDa

Other solid tumors

20

40.0%

65.0%

52.6%

75.0%

• Novel humanized dAb against PDL1

• Low immunogenicity

• Mutant Fc to eliminate ADCC/CDC activity

• Stable

Envafoleimab and Anti-androgenic Combinations

Envafoleimab + Envafoleimab


Preclinical	IND	Phase I	Phase II	Phase III	NDA
-------------	-----	---------	----------	-----------	-----

Phase II trial of Envafoleimab combination therapy in solid tumor patients



SIM0235: Humanized anti-TNFR2 monoclonal antibody

New targets for tumor immunity



TNFR2^{1,2,3} on the cell surface:

of TNFR2 by endogenous TNF, it

affects TNFR2-mediated immunosuppression and tumor cell proliferation.


Antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by Fc terminal has a direct killing effect on immunosuppressive cells, including tumor cells expressing TNFR2, regulatory T cells (Tregs) and bone marrow-derived suppressor cells (MDSCs).

TNFR2 Humanized Animal Model:
Single Drug Efficacy


2500

G1: Vehicle

G2: SIM1811-03, 3 mg/kg, i.p.



Animal Model Data: Combination
with Anti-PD-L1 Antibody



It can specifically recognize TN

• By blocking the activation of

• A

b


c

(T


SIM0270: BBB permeable, tumor tissue-enriched,

BBB permeable, tumor tissue-enriched,

BBB permeable, tumor tissue-enriched,



Name	R&D company	Clinical phase	Oral	BBB permeability
Fulvestrant	Astrazeneca	Approved SERD compound Annual sales exceeding 1 billion US dollars	Yes	Yes
SIM0270	Simcere	Phase I	Yes	Yes



CORE ADVANTAGES

SIM0270 showed superior in vivo and in vitro efficacy to Fulvestrant, comparable to those of GDC-9545, a leading compound in clinical practice.

SIM0270 showed a significantly better brain-blood ratio than alternative compounds and




simultaneously inhibited tumor growth with GDC-9545 in ER+ breast cancer model.

Phase I clinical trial started in 2021 and phase III expected in 2024

tumor growth combined with vivo

ER+ brain in situ model


Inhibit ER+ tumor growth




Milestones 2021-2022

2021

2022 Goal



Operational Excellence Driving Simcere's Purpose and R&D Vision



Operational Excellence— New Asset Development

Client: Mineral Resources, substantial only, some minor

FR 15-0115 (COLO)

10/15/2021 8:15



Globalization to Further Extend Asset Value



Providing Today's Patients with Medicines of the Future



**Clinical
value-oriented**

**Innovative
pipelines**

**Operational
Excellence**

**Global R&D
Strategy**



Late-stage

Non-oncology Pipeline

James Chen, PhD

2

Overall Strategy

Focus on targets and disease of high unmet needs

Central Nervous System (CNS)

- Sanbexin®/Sanbexin sublingual indication expansions in China and globally

- Develop novel FIC compounds alone and in combination to further improve

Autoimmune

- Breakthrough therapy to address the limitations of current treatment
- Focus on rheumatology and




CNS/Autoimmune clinical strategies and highlights – clinical value and differentiation

Equation

Non-oncology Pipeline

CNS, Autoimmune, and the disease areas that have significant clinical needs in the future



Key Project Introduction.

CNS

CNS Clinical Focus

Subsegments of nervous system disease

Neurological drug R&D success	Few domestic	Both China unique and
-------------------------------	--------------	-----------------------

Challenges

China's Stroke Treatments Still Have Huge Gaps

Rate

Large Number Patients And Low Thrombolytic R

chemic
5-2019¹

About 30% of ischemic stroke patients miss the thrombolysis treatment window due to hospitalization later than 6h from onset.

Number of Discharged Patients with Ischemic and Hemorrhagic Stroke in China 2005-2016

(10000 person)

433

Proportion of patients

China receiving rt-PA within 3 hours of onset²

18.3%

83.6%

9 122 135 118 128


2017 2018 2019

ke

Ischemic Stroke Patients 5-year Recurrence Rate³⁻⁴

41%

Average thrombolytic rate



1. China Health Statistics Yearbook 2020

2. DOI: 10.3760/cma.j.cn112137-20210416-00914.

3. The lancet global health 10.1016/S2214-109X(20)300

4. China cardiovascular health and dis

Sanbexin® (Dabigatran Etexilate) Phase 3 Study


48 clinical centers across the country participated in the trial, including ~1200 subjects, and the data were also shared with the FDA and EMA.

with

Primary efficacy endpoint: Proportion of patients with mRS score ≤ 1 on day 90 of treatment.

OR: 1.81, $P = 0.0004$

OR: 1.42, 95%CI: 1.12~



Sanbexin® (Dabigatran Etexilate) Phase 3 Study

Sanbexin®: TASTE II Ischemic Stroke Reperfusion Study

Phase IV study to evaluate efficacy and neurological recovery of Sanbexin combined with early endovascular recanalization therapy in patients with Acute Ischemic Stroke (AIS)

- A phase IV study to evaluate efficacy and neurological recovery of Sanbexin combined with early endovascular recanalization therapy in patients with Acute Ischemic Stroke (AIS)



After vascular recanalization, Sanbexin can directly enter the ischemic site to promote the recovery of ischemic damaged brain tissue.

Protect the brain tissue from re-injury caused by ischemia-reperfusion injury.



The efficacy of new neuroprotective agent edaravone (S18001) combined with alteplase on AIS

significantly improve neurological function in stroke patients.

Sanbexin®: Hemorrhagic Stroke Indication

Preclinical study



Animal experiments showed that Sanbexin® could significantly improve the prognosis of cerebral hemorrhage.

- Sanbexin® administration two hours after the onset of collagenase-induced ICH could significantly relieve the cerebral edema caused by hemorrhagic stroke.

the treatment of cerebral hemorrhage



- The trial will be launched in the end of 2022.

NCT300



Sanbexin Sublingual Tablet

Further expand the effectiveness of Sanbexin in stroke treatment and recovery



Sanbexin Sublingual Tablet is a new type of stroke treatment and recovery drug. It is a sublingual tablet that can be taken at home or in the hospital. It is a new type of stroke treatment and recovery drug that can be taken at home or in the hospital. It is a new type of stroke treatment and recovery drug that can be taken at home or in the hospital.

	Phase I Clinical Trial	Phase II Clinical Trial
Study Design	Randomized, Double-blind, Placebo-controlled	Randomized, Double-blind, Placebo-controlled
Study Population	33 Patients	33 Patients
Study Period	28 Days	28 Days

Sanbexin Sublingual Tablet is a new type of stroke treatment and recovery drug. It is a sublingual tablet that can be taken at home or in the hospital. It is a new type of stroke treatment and recovery drug that can be taken at home or in the hospital.

Sanbexin Sublingual Tablet

Phase III clinical study in the treatment of acute ischemic stroke

Primary endpoint: proportion of subjects with mRS ≤ 1 on day 90 of treatment

of participants with mRS ≤ 1

Randomized
1:1
double-blind
parallel control

Sanbexin Sublingual tablet

placing a tablet under the tongue to obtain the sublingual administration, every 12 ± 1 h, for 14 days (28 times) in a consecutive manner

achieve database

Placebo Sublingual tablet

Whole course management of stroke (N=914)

- June 28, 2021, the first case of the subject's delivery
- December 31, 2021, achieving the enrollment of 519 subjects, exceeding expectations
- March 12, 2022, 783 subjects were enrolled
- Interim analysis expected in 2022H1 and complete

recruitment of all subjects, and achieve database lock


Randomized
double-blind
parallel control

Phase I clinical trial in China

Cortex: Extracellular Space



- IND approval: April 2021
- FIH: December 2021
- Phase I completion: 2023



any/long-term intervention based on a combination of multiple mechanisms

01 Reduce neuroinflammation

1. Inflammation: Neuroinflammation, Microglia

2. Inflammation: Neuroinflammation, Microglia

3. Inflammation: Neuroinflammation, Microglia

1. Inflammation: Neuroinflammation, Microglia

2. Inflammation: Neuroinflammation, Microglia

3. Inflammation: Neuroinflammation, Microglia

4. Inflammation: Neuroinflammation, Microglia

5. Inflammation: Neuroinflammation, Microglia

6. Inflammation: Neuroinflammation, Microglia

7. Inflammation: Neuroinflammation, Microglia

QPCT oral small molecule inhibitor




Key Project Introduction

Autoimmune

Iremod® New Indication: Sjogren's Syndrome

The efficacy and safety for RA have been verified for over 10 years

score, hyperglobulinemia and ESR of the patients were significantly lower than those at baseline




The world's first and China's only approved iguratimod (IGU) compound



The only domestically developed

ARD approved in
st decade



small-molecule DMARD
the past

LNK01001: Selective Jak1 Inhibitor

March 18, 2022, Simcere entered into a collaboration agreement with Lynk Pharmaceuticals to obtain the exclusive commercialization interest of LNK01001 for rheumatoid arthritis (RA) and Ankylosing spondylitis (AS) indications in China. Lynk Pharmaceuticals will be responsible for the clinical development of LNK01001.



Phase 1 PK and PD summary:


Phase I studies in healthy subjects demonstrates good safety and tolerability

- SAD:** PK parameters increase proportionally in the range of 6 mg to 84 mg along with the dose. Exposure in vivo to LNK01001 AUC and Cmax are linearly kinetic.
- MAD:** AUCs with multiple administrations on D1 & D7: basically consistent; basically, no accumulation in the body
- No dose-related incidence of adverse events.**

- No TEAE above >2 or
- No SAE;
- No death-causing TEAE
- No TEAE leading to dis

- FE:** AUC shows no significant change with fasting or eating state; post administration has no significant effect on the metabolism elimination of half life period($t_{1/2}$). Not change significant
- PD:** good Pharmacokinetic and Pharmacodynamic relation

Milestones Expected in 2022





Strengthening BD, M&A and Investments within a Global Strategy

Kevin Oliver , PhD
SVP, Global Health

Simcere's BD/M&A Team has high credibility, is diverse and has a deep reputation in the industry.

2018, 2019, 2020

Professional (ASAP) Excellence Awards

30

250+

201

Professional (ASAP) Excellence Awards

acquisitions integrated collectively

TRANSACTIONS



Kevin Oliver
SVP Global Head of BD&L



Yuehua Cong
ED Head of BD&L EU



Yves McMullen
Head of US Transactions and Global Invest.



Gaobo Zhou.
CIO, Head of BD&L AP




Michael Bayewitch
ED, US AP Transaction



S&E




Catherine Abbadie
Global Head of CNS S&E



Matthias Höss
Global Head of Autoimmune

Markus Decker

Global Head, Oncology S&E



LEGAL




Ian Liu
Head of Legal & Gov't Affairs, US EU




AM




Mark Coffin
VP Global Alliance Management




BD is geographically established to become 'Partner of Choice'




Global center of excellence, centered in Boston, will focus on six key, global operational strategies



People, Integrity, Trust and proven Capabilities are critical to being 'Partner of Choice'



Sincere values its existing 35+ alliances and IP positions



Strategically driven R&D: In licensing interests in Oncology

drug screening

Drug targets with First-in-class and/or Best-in-

into preclinical) with innovative

mechanisms not already present in the market

First-in-class

Modality specific

Partnering with academia –

Global licensing=rights and an

R&A

Small molecule and biologics

Focus on high unmet need indications that are TOP10 prevalent tumor types in China.

Focus on assets with clinical DoC in relevant indications

Novel drug classes/modalities (RNA therapeutics, Tetra-

specific GPCR, gastroprotection)

Novel ex-vivo functional screening platforms (Novel types of SL interactions)

Flexible partnership models (In-licensing/Co-dev, R&D collaborations, JV & Equity Investment, M&A)

Innovative modalities

High-throughput structure-based (Challenging Targets)

Novel drug


Earlier stage assets

Novel platform capability part


relationships that lead to global engine to feed the pipeline

Late / commercial stage M&A

Strategically-driven BD: In-licensing interests in CNS and Autoimmune



Exclusive License Agreement for Trilaciclib in Greater China



BioWorld™

Simcere **inhibitor from G1**

Therapeutics in \$1.70M deal

China's Simcere Pharmaceutical

NYSE

people with cancer treated with


CDK4/6 Inhibitor

Cell Lung Cancer (SCLC)

Received

By Ebo Mak


Exclusive License Agreement for small molecule, PQ912, and biologic in Greater China



Phase 2 N3pE Amyloid-Targeting Medicines to Treat Alzheimer's Disease.

Best efficacy among available clinical opportunities
patients

Sincere as Partner of Choice in China... with global ambitions



Q & A

ATTENDEES



HOST:





先声药业
Simcere

SIMCERE PHARMACEUTICAL GROUP LIMITED

2022 R&D DAY

STOCK CODE: 2096.HK



IR CONTACTS



Tel: +86(25)8556 6366 Email: ir@simcere.com

Postal Address: Board Office, Simcere Pharmaceutical Group Limited 699-18 Xuanwu Avenue,
Xuanwu District, Nanjing, Jiangsu